Markets
Stocks
Mutual Funds & ETF's
Sectors
Tools
Overview
Market News
Currencies
International
Search InvestCenter
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Top Indices
DJI
Nasdaq Composite
SPX
My Portfolio
Arcutis Biotherapeutics Inc
(NQ:
ARQT
)
10.65
+0.40 (+3.95%)
Streaming Delayed Price
Updated: 2:21 PM EST, Nov 13, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
All News about Arcutis Biotherapeutics Inc
< Previous
1
2
3
4
5
6
7
Next >
Arcutis’ ZORYVE® (roflumilast) Awarded Best Eczema Treatment by Glamour
Today 8:00 EST
From
Arcutis Biotherapeutics, Inc.
Via
GlobeNewswire
Arcutis Announces Third Quarter 2024 Financial Results and Provides Business Update
November 06, 2024
From
Arcutis Biotherapeutics, Inc.
Via
GlobeNewswire
Arcutis Presents Positive Patient-Reported Outcome Data for ZORYVE® (Roflumilast) Cream 0.15% in Atopic Dermatitis at American College of Allergy, Asthma and Immunology 2024 Annual Scientific Meeting
October 24, 2024
From
Arcutis Biotherapeutics, Inc.
Via
GlobeNewswire
Assessing Arcutis Biotherapeutics: Insights From 4 Financial Analysts
August 28, 2024
Via
Benzinga
Peeling Back The Layers: Exploring Arcutis Biotherapeutics Through Analyst Insights
July 30, 2024
Via
Benzinga
Top 3 Health Care Stocks That Could Lead To Your Biggest Gains In Q4
October 22, 2024
Via
Benzinga
Arcutis Announces Health Canada Approval of ZORYVE® (Roflumilast) Foam 0.3% to Treat Seborrheic Dermatitis in Individuals 9 Years of Age and Older
October 18, 2024
From
Arcutis Biotherapeutics, Inc.
Via
GlobeNewswire
New Data Shows ZORYVE® (Roflumilast) Cream 0.15% Provided Consistent Improvement of Atopic Dermatitis in Individuals With Diverse Skin Types
September 25, 2024
From
Arcutis Biotherapeutics, Inc.
Via
GlobeNewswire
Arcutis Biotherapeutics Stock: A Deep Dive Into Analyst Perspectives (4 Ratings)
July 10, 2024
Via
Benzinga
FDA Accepts Arcutis’ Supplemental New Drug Application for ZORYVE® (roflumilast) Foam for the Treatment of Scalp and Body Psoriasis in Adults and Adolescents Ages 12 and Over
September 24, 2024
From
Arcutis Biotherapeutics, Inc.
Via
GlobeNewswire
Arcutis Announces Publication of ZORYVE® (roflumilast) Cream 0.15% Pivotal Results from Phase 3 INTEGUMENT-1 and -2 Trials in Mild to Moderate Atopic Dermatitis in Journal of American Medical Association Dermatology
September 19, 2024
From
Arcutis Biotherapeutics, Inc.
Via
GlobeNewswire
Arcutis Completes Enrollment of Phase 1b Alopecia Areata Study Evaluating ARQ-255
September 05, 2024
From
Arcutis Biotherapeutics, Inc.
Via
GlobeNewswire
Arcutis Announces Positive Long-Term Results of Roflumilast Cream 0.05% Show Durable and Improved Efficacy Over Time and Favorable Safety Profile in Treatment of Children Aged 2 to 5 with Mild to Moderate Atopic Dermatitis
August 28, 2024
From
Arcutis Biotherapeutics, Inc.
Via
GlobeNewswire
CAVA Group Posts Strong Q2 Results, Joins Bilibili, Workday And Other Big Stocks Moving Higher On Friday
August 23, 2024
Via
Benzinga
Titan Machinery Reports Weak Preliminary Results, Joins Precigen, Gogoro And Other Big Stocks Moving Lower In Thursday Pre-Market Session
August 15, 2024
Via
Benzinga
CORRECTION – Arcutis Announces Second Quarter 2024 Financial Results and Provides Business Update
August 14, 2024
From
Arcutis Biotherapeutics, Inc.
Via
GlobeNewswire
ARQT Stock Earnings: Arcutis Biotherapeutics Beats EPS, Beats Revenue for Q2 2024
August 14, 2024
ARQT stock results show that Arcutis Biotherapeutics beat analyst estimates for earnings per share and beat on revenue for the second quarter of 2024.
Via
InvestorPlace
Arcutis Announces Second Quarter 2024 Financial Results and Provides Business Update
August 14, 2024
From
Arcutis Biotherapeutics, Inc.
Via
GlobeNewswire
Arcutis Announces ZORYVE® U.S. Co-promote Agreement with Kowa Pharmaceuticals America, Inc.
July 29, 2024
From
Arcutis Biotherapeutics, Inc.
Via
GlobeNewswire
Arcutis Launches ZORYVE® (roflumilast) Cream 0.15% for the Treatment of Atopic Dermatitis
July 29, 2024
From
Arcutis Biotherapeutics, Inc.
Via
GlobeNewswire
7 Biotech Stocks to Keep on Your Clinical Radar
July 23, 2024
Biotech stocks have always been relevant. However, with the latest shift in the political race, this sector is bound to grab more eyeballs.
Via
InvestorPlace
Arcutis Submits Supplemental New Drug Application for ZORYVE® (roflumilast) Foam to the FDA for the Treatment of Scalp and Body Psoriasis in Adults and Adolescents Ages 12 and Over
July 23, 2024
From
Arcutis Biotherapeutics, Inc.
Via
GlobeNewswire
Arcutis to Host ZORYVE® (Roflumilast) Cream 0.15% FDA Approval Call With KOL
July 22, 2024
From
Arcutis Biotherapeutics, Inc.
Via
GlobeNewswire
FDA Approves Expanded Use Of Arcutis Biotherapeutics' Eczema Drug For Patients As Young As 6 Years
July 10, 2024
FDA approved Arcutis Biotherapeutics' sNDA for Zoryve cream 0.15% for mild to moderate atopic dermatitis in patients aged six and older. Zoryve provides a steroid-free treatment option. Significant...
Via
Benzinga
Exposures
Product Safety
FDA Approves Arcutis’ ZORYVE® (roflumilast) Cream 0.15% for the Treatment of Atopic Dermatitis in Adults and Children Down to 6 Years of Age
July 09, 2024
From
Arcutis Biotherapeutics, Inc.
Via
GlobeNewswire
Arcutis Provides Update on sNDA for Roflumilast Cream 0.15% for Atopic Dermatitis
July 09, 2024
From
Arcutis Biotherapeutics, Inc.
Via
GlobeNewswire
Intapp, ServiceNow And Other Big Stocks Moving Lower In Monday's Pre-Market Session
July 08, 2024
Via
Benzinga
The 7 Best Under $10 Stocks to Buy in July 2024
July 06, 2024
We’re finding big opportunities in some of the best stocks under $10 a share. In fact, here are seven you may want to jump into now.
Via
InvestorPlace
Vanda Pharmaceuticals And Other Big Stocks Moving Lower In Thursday's Pre-Market Session
June 20, 2024
Via
Benzinga
Have $5-10? 7 Affordable Stocks That Are About to Breakout.
June 13, 2024
These stocks are already showing gains this year, but they are all still affordable stocks ready to breakout.
Via
InvestorPlace
< Previous
1
2
3
4
5
6
7
Next >
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.